Laurus Labs Ltd - Share Price
LAURUSLABS
Laurus Labs LtdFinancials
Laurus Labs LtdNews & Updates
Apr 30,2021 03:39 PM
On 15 July 2021
Board of Laurus Labs recommends third interim dividend Apr 30,2021
Laurus Labs fixes record date for 3rd interim dividend Apr 30,2021
Laurus Labs consolidated net profit rises 169.34% in the March 2021 quarter Apr 29,2021
Laurus Labs Q4FY21 PAT nearly trebles to Rs297cr Apr 29,2021
Laurus Labs to conduct board meeting Apr 23,2021
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Ltd | 3,221.50 | 0.00 | 46,325.98 | 106.22 | 0.18 | 2,367.01 | 347.59 |
| Laurus Labs Ltd | 593.55 | 33.29 | 31,828.57 | 292.78 | 0.34 | 1,398.74 | 50.54 |
| Dr Lal Pathlabs Ltd | 3,176.20 | 94.66 | 26,516.17 | 78.70 | 0.63 | 404.10 | 146.04 |
| Max Healthcare Institute Ltd | 250.45 | 0.00 | 24,119.65 | 7.24 | 0.00 | 330.80 | 61.49 |
| Fortis Healthcare Ltd | 232.00 | 0.00 | 17,560.33 | -41.10 | 0.00 | 194.82 | 117.64 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Laurus Labs LtdSummary & Reports
Laurus Labs is a leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (P... More
Registered Office
Plot No 21 Jawaharlal Nehru,Pharma City Parawada,Visakhapatnam, Andhra Pradesh,531021
Tell. : +91-891-3061222
Website : http://www.lauruslabs.com
Email : secretarial@lauruslabs.com
Registrar Office
Karvy Selenium Tow-B, Nanakramguda, Hyderabad-500032 INDIA
Tell. : +91-40-67162222
Website : www.kfintech.com
Email : einward.ris@kfintech.com
Reports by laurus-labs-ltd-share-price
Latest Release by laurus-labs-ltd-share-price
Result Express
Laurus Labs Ltd's Q3FY19 consolidated net profit declines 48.9% yoy to Rs17.82cr : Misses Estimates
Jun 19, 2021 09:30 AM
The company’s consolidated revenue stood at Rs529.46cr, up 10.55% yoy but down 10% qoq.
Shareholding Snapshot
Loading ...
| Mar - 2021 | |
|---|---|
| Promoter | - |
| Foreign | 0.00% |
| Indian | 27.45% |
| Total Promoter | 27.45% |
| Non Promoter | - |
| Institutions | 24.24% |
| Non-Institutions | 48.31% |
| Total Non-Promoter | 72.55% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Dividend
Annc. Date
29 Apr 2021
Effective. Date
11 May 2021
Divi. Type
Interim 3
Divi.(%)
40
Divi. Amt.
0.8
Laurus Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on A... More
Purpose
Board Meeting
Exp. Date
29 Apr 2021
Annc. Date
22 Apr 2021
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is schedul... More
Purpose
Dividend
Annc. Date
28 Jan 2021
Effective. Date
08 Feb 2021
Divi. Type
Interim 2
Divi.(%)
20
Divi. Amt.
0.4
The Board of Directors of the Company in their meeting held on January 28, 2021 have approved for th... More
Purpose
Board Meeting
Exp. Date
28 Jan 2021
Annc. Date
19 Jan 2021
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is schedul... More
